News

11 January 2017

Company Update

Physiomics plc (AIM: PYC) is pleased to announce that it is making good progress towards the strategic objectives announced in its most recent full year results (RNS 27th October 2016 and subsequent printed annual report circulated to shareholders).
On the 5th December 2016 Physiomics announced an initial payment by Sareum for modelling carried out by the Company in 2010 to support the identification of an optimal combination regime of a Chk1 inhibitor and a DNA-targeting chemotherapy using the pre-clinical version of the Company’s Virtual Tumour technology. The payment was triggered by a number of pre-conditions including the announcement on 27th September 2016 by Sareum that its partner, the CRT Pioneer Fund, had licensed exclusive and worldwide rights for a Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI).

Please see here for full information.